Humacyte, Inc. - Common Stock HUMA 深 沪
已收盘 10-31 16:00:00 美东时间
1.67
+0.050
+3.09%
华盛通- 最 高1.67
- 今 开1.65
- 成交量 326.26万股
- 最 低 1.60
- 昨 收 1.62
- 总市值 2.66亿
- 52周最高 6.77
- 市盈率 静 --
- 换手率 2.05%
- 52周最低 1.15
- 委 比 -99.64%
- 总股本 1.59亿
- 历史最高 17.45
- 量 比 1.01
- 振 幅 4.32%
- 历史最低 1.15
- 每 手 1
- 风险率 1.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Humacyte Publishes Study Showing Its Bioengineered Vessel, Symvess Demonstrated Comparable Short-Term Outcomes To Autologous Vein Grafts In Treating Extremity Arterial Trauma, With Similar Results For Patency, Limb Salvage, And Infection Rates
Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication of a new study
10-30 20:10
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
BTIG Maintains Buy on Humacyte, Lowers Price Target to $6
BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $7 to $6.
10-13 20:06
Humacyte Announces $60M Stock and Warrants Offering
Humacyte ( ($HUMA) ) has provided an update. On October 6, 2025, Humacyte, Inc....
10-08 05:54
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering
Humacyte, a biotechnology company, raised approximately $60 million through a registered direct offering of common stock and warrants to institutional investors. The offering involves 28,436,018 shares of common stock and warrants to purchase an equal number of shares, with an exercise price of $2.11 per share. The transaction is expected to close by October 8, 2025, subject to customary conditions. Proceeds will support the company's growth init...
10-07 13:00
Humacyte Publishes Long-Term Results For Ukrainian Patients Treated In Real-World Combat Setting With Symvess In Military Medicine
- Results published in Oxford Academic's Military Medicine Journal -- After up to 18 months of follow-up patients were observed to have zero infections, amputations or deaths and a high rate of patency -
10-06 20:17
Humacyte Secures U.S. Patent For Bioengineered Esophagus Composition Using Proprietary Regenerative Tissue Engineering Platform
– Patent covers esophagus produced using Humacyte's proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus –– Patent provides coverage into 2041 for the composition of novel bioengineered esophagus –
09-29 20:16
Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
Humacyte, Inc. has been granted a U.S. patent for a bioengineered esophagus produced using its proprietary regenerative tissue engineering platform, offering protection until 2041. This expands the company's patent coverage for bioengineered trachea, esophagus, and urinary conduits in multiple regions, including the U.S., Europe, Canada, and Australia. The advanced tissue constructs are part of Humacyte's broad product pipeline and are currently ...
09-29 12:00
Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback
Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Small caps rally 43% since tariff-driven selloff.
09-19 03:08
Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)
Humacyte announced positive preclinical results for its coronary tissue engineered vessel (CTEV) in a non-human primate model, showing sustained patency, adaptive remodeling, and recellularization with host cells. The CTEV, designed as an alternative to traditional grafts, demonstrated potential superiority in reducing size mismatch and improving long-term outcomes. Humacyte plans to advance CTEV into first-in-human studies, with an IND applicati...
09-18 11:00
